Technical University Munich-ko ikertzaileekin lankidetzan egindako argitalpenak (33)

2024

  1. Changes in the prevalence of mental health problems during the first year of the pandemic: a systematic review and dose-response meta-analysis

    BMJ Mental Health, Vol. 27, Núm. 1

  2. Transatlantic analysis of patient profiles and mid-term survival after isolated coronary artery bypass grafting: a head-to-head comparison between the European DuraGraft Registry and the US STS Registry

    Frontiers in Cardiovascular Medicine, Vol. 11

  3. Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 5, pp. 994-1004.e10

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy – Molecular radiotherapy

    Physica Medica, Vol. 116

  3. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

2022

  1. Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity

    Human Genetics, Vol. 141, Núm. 1, pp. 147-173

  2. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

    Human Molecular Genetics, Vol. 31, Núm. 23, pp. 3945-3966

  3. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  4. Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries (Nature, (2022), 611, 7934, (115-123), 10.1038/s41586-022-05165-3)

    Nature

  5. Stroke genetics informs drug discovery and risk prediction across ancestries

    Nature, Vol. 611, Núm. 7934, pp. 115-123

2021

  1. Long-term follow-up after recanalisation of aortic arch atresia

    EuroIntervention, Vol. 16, Núm. 15, pp. E1274-E1280

  2. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2020

  1. Corrigendum to ‘Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia’ (European Journal of Vascular & Endovascular Surgery (2019) 58(1S) (S1–S109.e33), (S1078588419303806), (10.1016/j.ejvs.2019.05.006))

    European Journal of Vascular and Endovascular Surgery

  2. Corrigendum to “Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischaemia” [Eur J Vasc Endovasc Surg 58 (1S) (2019) 1–109>] (European Journal of Vascular & Endovascular Surgery (2019) 58(1S) (S1–S109.e33), (S1078588419303806), (10.1016/j.ejvs.2019.05.006))

    European Journal of Vascular and Endovascular Surgery

  3. Luspatercept in patients with lower-risk myelodysplastic syndromes

    New England Journal of Medicine, Vol. 382, Núm. 2, pp. 140-151

2019

  1. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia

    European Journal of Vascular and Endovascular Surgery, Vol. 58, Núm. 1, pp. S1-S109.e33

  2. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations

    Parkinsonism and Related Disorders, Vol. 60, pp. 138-145

2018

  1. A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS)

    Acta Ophthalmologica, Vol. 96, Núm. 8, pp. e942-e949

2016

  1. Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists

    British Journal of Haematology, Vol. 174, Núm. 4, pp. 610-623